Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment
Authors:
- Marco BarbieriMBMarco Barbieri
- Michael F DrummondMDMichael F Drummond
- Jaume Puig JunoyJJJaume Puig Junoy
- Miguel Angel Casado GómezMGMiguel Angel Casado Gómez
- F Javier Ballina GarcíaFGF Javier Ballina García
- Pilar Blasco SeguraPSPilar Blasco Segura
- José Luis Poveda AndrésJAJosé Luis Poveda Andrés
- 1 December 2007
- journal article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 7 (6) , 613-626
Abstract
Clinical trials and economic models have showed that anti-TNF agents are effective and cost effective compared with standard therapies (mainly disease-modifying antirheumatic drugs) in patients with rheumatoid arthritis. However, no head-to-head clinical trials between these agents are available and the relative effectiveness and cost-effectiveness is uncertain. We have conducted a literature review in order to identify full economic evaluations that compared two or more TNF antagonists. A description of each study was given and key methodological issues identified. These included methods for evidence synthesis, model characteristics and methods to address uncertainty in model parameters. Important differences in methodological features and results have been found between studies. More attention in future studies should be given to methods for indirect comparisons between the biological agents.Keywords
This publication has 27 references indexed in Scilit:
- Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritisStatistics in Medicine, 2006
- Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid ArthritisPharmacoEconomics, 2006
- Simultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ, 2005
- Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trialAnnals of the Rheumatic Diseases, 2005
- Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in SwedenAnnals of the Rheumatic Diseases, 2005
- Combination of direct and indirect evidence in mixed treatment comparisonsStatistics in Medicine, 2004
- Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UKRheumatology, 2003
- Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern SwedenAnnals of the Rheumatic Diseases, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- The death of cost‐minimization analysis?Health Economics, 2001